April 3, 2024
Recent Articles
Press Releases
April 10, 2024
Trumbull, CT - The Rett Syndrome Research Trust (RSRT) has taken a significant stride in the pursuit of innovative genetic medicines for Rett ...
March 28, 2024
Trumbull, CT - PMD Solutions, a leading provider of innovative healthcare technologies, is proud to announce its partnership with the Rett ...
January 31, 2024
The Rett Syndrome Research Trust (RSRT) continues to spearhead groundbreaking research in its pursuit of a cure for Rett syndrome. RSRT has ...
January 16, 2024
The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research. ...
November 9, 2023
The Rett Syndrome Research Trust (RSRT) is excited to announce the launch of the Rett Syndrome Global Registry, a fully-remote platform for ...
October 10, 2023
Trumbull, CT – The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome ...
February 21, 2023
TRUMBULL, CT — The Rett Syndrome Research Trust (RSRT) is excited to announce a $1.1 million dollar research award to Dina Katabi, PhD, and her ...
February 7, 2023
TRUMBULL, CT — Alba Tull has made a generous donation of $500,000 to the Rett Syndrome Research Trust (RSRT) for a clinical study to determine ...
Rett In The News
UMASS Chan Medical School
March 4, 2024
UMASS Chan Medical School announces the $2.3 million award from RSRT to develop genetic medicines for Rett syndrome.
ProQR
January 5, 2024
ProQR, a biotech company in The Netherlands, and RSRT have initiated a collaboration to develop RNA editiing therapeutics for Rett syndrome. RSRT has made an initial $1 million award to ProQR.
Neurogene
January 5, 2024
Key highlights from Neurogene's update include approval to dose patient #3; clearance to initiate a trial in the UK; plans to expand the US trial to more patients and to test a higher dose; expect to share data on US trial in Q4 2024.
EndPointsNews
January 2, 2024
Anavex Life Sciences, a biotech company that has come under fire for trying to spin its clinical trial results, wants to claim partial success on a late-stage trial in kids with Rett syndrome, a rare genetic neurological disorder. However, the biotech’s own ad-hoc analysis says otherwise.